臨床検査56巻2号

2012年02月発行

今月の主題 生理活性脂質 話題

リゾリン脂質と肝臓疾患

著者： 池田均¹

所属機関： ¹東京大学大学院医学系研究科臨床病態検査医学分野

ページ範囲：P.209 - P.212

1．はじめに

　近年，リゾリン脂質メディエーターであるリゾホスファチジン酸(lysophosphatidic acid；LPA)とスフィンゴシン-1-リン酸(sphingosine-1-phosphate；S1P)の多彩な生理活性と生体内における役割の解明は飛躍的に進んだ^1,2)．LPA，S1Pについて特徴的である点は，他の生体内メディエーターに比して血中濃度が高く，in vitroの細胞系で作用を及ぼす濃度に非常に近いということである．すなわち，メディエーターとして多彩な作用を有し，血中でも作用を及ぼす可能性が高いレベルで豊富に存在するため，受容体発現量の変化により，その作用のオンオフが調節されている可能性も推定され，実際に受容体アゴニスト，アンタゴニストが疾患治療に応用されつつある．

　いずれにせよ，LPA，S1Pともに様々な疾患への関与が報告されてきており，本稿では，特に肝臓疾患における役割についての報告を概観する．

参考文献

1) Mills GB, Moolenaar WH : The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer　3：582-591，2003

2) Alvarez SE, Milstien S, Spiegel S : Autocrine and paracrine roles of sphingosine-1-phosphate. Trends Endocrinol Metab　18：300-307，2007

3) Ikeda H, Yatomi Y, Yanase M, et al : Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture. Biochem Biophys Res Commun　248：436-440，1998

4) Yanase M, Ikeda H, Matsui A, et al : Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells : association with rho-kinase. Biochem Biophys Res Commun　277：72-78，2000

5) Ikeda H, Nagashima K, Yanase M, et al : Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol　285：G880-886，2003

6) Watanabe N, Ikeda H, Nakamura K, et al : Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity. Life Sci　81：1009-1015，2007

7) Watanabe N, Ikeda H, Nakamura K, et al : Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol　41：616-623，2007

8) Stracke ML, Krutzsch HC, Unsworth EJ, et al : Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem　267：2524-2529，1992

9) Tokumura A, Majima E, Kariya Y, et al : Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem　277：39436-39442，2002

10) Umezu-Goto M, Kishi Y, Taira A, et al : Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol　158：227-233，2002

11) Jansen S, Andries M, Vekemans K, et al : Rapid clearance of the circulating metastatic factor autotaxin by the scavenger receptors of liver sinusoidal endothelial cells. Cancer Lett　284：216-221，2009

12) Nakagawa H, Ikeda H, Nakamura K, et al : Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta　412：1201-1206，2011

13) Kremer AE, Martens JJ, Kulik W, et al : Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology　139：1008-1018，2010

14) Zhang G, Zhao Z, Xu S, et al : Expression of autotaxin mRNA in human hepatocellular carcinoma. Chin Med J (Engl)　112：330-332，1999

15) Cooper AB, Wu J, Lu D, et al : Is Autotaxin (ENPP2) the Link between Hepatitis C and Hepatocellular Cancer? J Gastrointest Surg　11：1628-1634，2007

16) Davaille J, Gallois C, Habib A, et al : Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway. J Biol Chem　275：34628-34633，2000

17) Ikeda H, Yatomi Y, Yanase M, et al : Biological activities of novel lipid mediator sphingosine 1-phosphate in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol　279：G304-310，2000

18) Davaille J, Li L, Mallat A, et al : Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts. J Biol Chem　277：37323-37330，2002

19) Ikeda H, Nagashima K, Yanase M, et al : Sphingosine 1-phosphate enhances portal pressure in isolated perfused liver via S1P2 with Rho activation. Biochem Biophys Res Commun　320：754-759，2004

20) Ikeda H, Satoh H, Yanase M, et al : Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5．Gastroenterology　124：459-469，2003

21) Im YJ, Im DS, Lee YK, et al : Study on action mode of sphingosine 1-phosphate in rat hepatocytes. J Pharmacol Sci　97：443-446，2005

22) Zheng DM, Kitamura T, Ikejima K, et al : Sphingosine 1-phosphate protects rat liver sinusoidal endothelial cells from ethanol-induced apoptosis : Role of intracellular calcium and nitric oxide. Hepatology　44：1278-1287，2006

23) Serriere-Lanneau V, Teixeira-Clerc F, Li L, et al : The sphingosine 1-phosphate receptor S1P2 triggers hepatic wound healing. FASEB J　21：2005-2013，2007

24) Ikeda H, Watanabe N, Ishii I, et al : Sphingosine 1-phosphate regulates regeneration and fibrosis after liver injury via sphingosine 1-phosphate receptor 2．J Lipid Res　50：556-564，2009

25) Li C, Kong Y, Wang H, et al : Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol　50：1174-1183，2009

26) Li C, Jiang X, Yang L, et al : Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol　175：1464-1472，2009

27) Li C, Zheng S, You H, et al : Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol　54：1205-1213，2011

28) Liu X, Yue S, Li C, et al : Essential roles of sphingosine 1-phosphate receptor types 1 and 3 in human hepatic stellate cells motility and activation. J Cell Physiol　226：2370-2377，2011

29) Ikeda H, Ohkawa R, Watanabe N, et al : Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta　411：765-770，2010